IL293671A - רנ" א מדריך אנטיסנס עם איזור פונקציונאלי נוסף לעריכת רנ" א מטרה - Google Patents

רנ" א מדריך אנטיסנס עם איזור פונקציונאלי נוסף לעריכת רנ" א מטרה

Info

Publication number: IL293671A
Authority: IL; Israel
Prior art keywords: region; sequence; guide rna; base sequence; rna
Prior art date: 2019-12-09

Application number

IL293671A

Other languages

English (en)

Original Assignee

Astellas Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-12-09

Filing date

2020-12-08

Publication date

2022-08-01

2020-12-08 Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc

2022-08-01 Publication of IL293671A publication Critical patent/IL293671A/he

Links

108020005004 Guide RNA Proteins 0.000 title claims description 358
230000000692 anti-sense effect Effects 0.000 title claims description 216
108091032973 (ribonucleotides)n+m Proteins 0.000 title claims description 191
102000039446 nucleic acids Human genes 0.000 claims description 134
108020004707 nucleic acids Proteins 0.000 claims description 134
150000007523 nucleic acids Chemical class 0.000 claims description 133
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 110
210000004027 cell Anatomy 0.000 claims description 75
239000013604 expression vector Substances 0.000 claims description 75
230000006870 function Effects 0.000 claims description 75
102000039471 Small Nuclear RNA Human genes 0.000 claims description 68
238000000034 method Methods 0.000 claims description 56
108091026838 U1 spliceosomal RNA Proteins 0.000 claims description 40
108091026822 U6 spliceosomal RNA Proteins 0.000 claims description 40
239000008194 pharmaceutical composition Substances 0.000 claims description 39
108091026823 U7 small nuclear RNA Proteins 0.000 claims description 36
230000000295 complement effect Effects 0.000 claims description 32
108020005075 5S Ribosomal RNA Proteins 0.000 claims description 30
230000015572 biosynthetic process Effects 0.000 claims description 27
230000004807 localization Effects 0.000 claims description 26
102000040430 polynucleotide Human genes 0.000 claims description 26
108091033319 polynucleotide Proteins 0.000 claims description 26
239000002157 polynucleotide Substances 0.000 claims description 26
230000006641 stabilisation Effects 0.000 claims description 24
238000011105 stabilization Methods 0.000 claims description 24
101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 claims description 21
239000000546 pharmaceutical excipient Substances 0.000 claims description 21
101000742223 Homo sapiens Double-stranded RNA-specific editase 1 Proteins 0.000 claims description 20
102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 claims description 17
241000700605 Viruses Species 0.000 claims description 16
210000000805 cytoplasm Anatomy 0.000 claims description 16
238000004519 manufacturing process Methods 0.000 claims description 16
102100038191 Double-stranded RNA-specific editase 1 Human genes 0.000 claims description 14
230000005764 inhibitory process Effects 0.000 claims description 9
238000012258 culturing Methods 0.000 claims description 6
108020004688 Small Nuclear RNA Proteins 0.000 claims description 4
239000002585 base Substances 0.000 description 396
108091029842 small nuclear ribonucleic acid Proteins 0.000 description 64
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 58
108091028043 Nucleic acid sequence Proteins 0.000 description 52
238000010357 RNA editing Methods 0.000 description 34
230000026279 RNA modification Effects 0.000 description 34
108020004418 ribosomal RNA Proteins 0.000 description 33
239000013598 vector Substances 0.000 description 33
239000002126 C01EB10 - Adenosine Substances 0.000 description 30
229960005305 adenosine Drugs 0.000 description 30
230000000694 effects Effects 0.000 description 30
239000013613 expression plasmid Substances 0.000 description 26
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 24
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 24
108090000623 proteins and genes Proteins 0.000 description 24
238000006243 chemical reaction Methods 0.000 description 23
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 20
230000000052 comparative effect Effects 0.000 description 18
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 18
239000013612 plasmid Substances 0.000 description 18
108090000765 processed proteins & peptides Proteins 0.000 description 18
125000003729 nucleotide group Chemical group 0.000 description 17
229920001184 polypeptide Polymers 0.000 description 17
102000004196 processed proteins & peptides Human genes 0.000 description 17
108700009124 Transcription Initiation Site Proteins 0.000 description 16
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 16
125000003275 alpha amino acid group Chemical group 0.000 description 16
229930010555 Inosine Natural products 0.000 description 15
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 15
229960003786 inosine Drugs 0.000 description 15
108020004999 messenger RNA Proteins 0.000 description 15
102000004169 proteins and genes Human genes 0.000 description 15
230000014509 gene expression Effects 0.000 description 14
230000003834 intracellular effect Effects 0.000 description 14
239000002773 nucleotide Substances 0.000 description 14
210000004940 nucleus Anatomy 0.000 description 13
230000036961 partial effect Effects 0.000 description 13
238000002474 experimental method Methods 0.000 description 12
108091008146 restriction endonucleases Proteins 0.000 description 12
238000001890 transfection Methods 0.000 description 12
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 11
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 10
230000027455 binding Effects 0.000 description 10
238000001514 detection method Methods 0.000 description 10
201000010099 disease Diseases 0.000 description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
239000002777 nucleoside Substances 0.000 description 10
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 10
229940045145 uridine Drugs 0.000 description 10
108020004414 DNA Proteins 0.000 description 9
230000008859 change Effects 0.000 description 9
238000013519 translation Methods 0.000 description 9
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 8
102000055025 Adenosine deaminases Human genes 0.000 description 8
108010092160 Dactinomycin Proteins 0.000 description 8
241000588724 Escherichia coli Species 0.000 description 8
239000002253 acid Substances 0.000 description 8
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 8
230000009286 beneficial effect Effects 0.000 description 8
229960000640 dactinomycin Drugs 0.000 description 8
210000003527 eukaryotic cell Anatomy 0.000 description 8
230000035772 mutation Effects 0.000 description 8
238000007480 sanger sequencing Methods 0.000 description 8
238000011144 upstream manufacturing Methods 0.000 description 8
108700007698 Genetic Terminator Regions Proteins 0.000 description 7
108700011259 MicroRNAs Proteins 0.000 description 7
239000002679 microRNA Substances 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
230000001737 promoting effect Effects 0.000 description 7
238000011160 research Methods 0.000 description 7
108091032955 Bacterial small RNA Proteins 0.000 description 6
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 6
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 6
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 6
230000002441 reversible effect Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
241000894006 Bacteria Species 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 5
108010051611 Signal Recognition Particle Proteins 0.000 description 5
102000013598 Signal recognition particle Human genes 0.000 description 5
108020004566 Transfer RNA Proteins 0.000 description 5
239000000074 antisense oligonucleotide Substances 0.000 description 5
238000012230 antisense oligonucleotides Methods 0.000 description 5
102000044898 human ADARB1 Human genes 0.000 description 5
239000006166 lysate Substances 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
108020004705 Codon Proteins 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
238000000137 annealing Methods 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
239000012634 fragment Substances 0.000 description 4
102000043770 human ADAR Human genes 0.000 description 4
238000003670 luciferase enzyme activity assay Methods 0.000 description 4
239000013600 plasmid vector Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
102000000331 Double-stranded RNA-binding domains Human genes 0.000 description 3
108050008793 Double-stranded RNA-binding domains Proteins 0.000 description 3
241000206602 Eukaryota Species 0.000 description 3
108090000331 Firefly luciferases Proteins 0.000 description 3
108091081406 G-quadruplex Proteins 0.000 description 3
108010052090 Renilla Luciferases Proteins 0.000 description 3
102100021651 SUN domain-containing ossification factor Human genes 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
230000003915 cell function Effects 0.000 description 3
230000009615 deamination Effects 0.000 description 3
238000006481 deamination reaction Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
229940029575 guanosine Drugs 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000004020 luminiscence type Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000009437 off-target effect Effects 0.000 description 3
239000002243 precursor Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
210000001324 spliceosome Anatomy 0.000 description 3
239000012096 transfection reagent Substances 0.000 description 3
108020004565 5.8S Ribosomal RNA Proteins 0.000 description 2
108091023037 Aptamer Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
108010053770 Deoxyribonucleases Proteins 0.000 description 2
102000016911 Deoxyribonucleases Human genes 0.000 description 2
108010033040 Histones Proteins 0.000 description 2
208000026350 Inborn Genetic disease Diseases 0.000 description 2
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
101710125418 Major capsid protein Proteins 0.000 description 2
208000024556 Mendelian disease Diseases 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
102000014450 RNA Polymerase III Human genes 0.000 description 2
108010078067 RNA Polymerase III Proteins 0.000 description 2
239000013614 RNA sample Substances 0.000 description 2
241000725643 Respiratory syncytial virus Species 0.000 description 2
102000004389 Ribonucleoproteins Human genes 0.000 description 2
108010081734 Ribonucleoproteins Proteins 0.000 description 2
108091061750 Signal recognition particle RNA Proteins 0.000 description 2
108020003224 Small Nucleolar RNA Proteins 0.000 description 2
102000042773 Small Nucleolar RNA Human genes 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
108091046869 Telomeric non-coding RNA Proteins 0.000 description 2
108091026828 U2 spliceosomal RNA Proteins 0.000 description 2
108091026831 U4 spliceosomal RNA Proteins 0.000 description 2
102000018686 U4-U6 Small Nuclear Ribonucleoprotein Human genes 0.000 description 2
108010091808 U4-U6 Small Nuclear Ribonucleoprotein Proteins 0.000 description 2
108091023045 Untranslated Region Proteins 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
238000000432 density-gradient centrifugation Methods 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
238000007901 in situ hybridization Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
230000002438 mitochondrial effect Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
125000003835 nucleoside group Chemical group 0.000 description 2
NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
238000001308 synthesis method Methods 0.000 description 2
230000008685 targeting Effects 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000007862 touchdown PCR Methods 0.000 description 2
STGXGJRRAJKJRG-JDJSBBGDSA-N (3r,4r,5r)-5-(hydroxymethyl)-3-methoxyoxolane-2,4-diol Chemical compound CO[C@H]1C(O)O[C@H](CO)[C@H]1O STGXGJRRAJKJRG-JDJSBBGDSA-N 0.000 description 1
108020004465 16S ribosomal RNA Proteins 0.000 description 1
108020004463 18S ribosomal RNA Proteins 0.000 description 1
RGDVNLHBCKWZDA-XLPZGREQSA-N 2'-deoxy-5-methyl-5'-cytidylic acid Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 RGDVNLHBCKWZDA-XLPZGREQSA-N 0.000 description 1
108091035699 6S / SsrS RNA Proteins 0.000 description 1
108091033409 CRISPR Proteins 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
102100026846 Cytidine deaminase Human genes 0.000 description 1
108010031325 Cytidine deaminase Proteins 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
102100024692 Double-stranded RNA-specific editase B2 Human genes 0.000 description 1
241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000686486 Homo sapiens Double-stranded RNA-specific editase B2 Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
108700036248 MT-RNR1 Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
108091093037 Peptide nucleic acid Proteins 0.000 description 1
241000235648 Pichia Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
102000009572 RNA Polymerase II Human genes 0.000 description 1
108010009460 RNA Polymerase II Proteins 0.000 description 1
108020005093 RNA Precursors Proteins 0.000 description 1
108091008103 RNA aptamers Proteins 0.000 description 1
238000003559 RNA-seq method Methods 0.000 description 1
238000011530 RNeasy Mini Kit Methods 0.000 description 1
238000011529 RT qPCR Methods 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 1
108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 1
108091026904 U11 spliceosomal RNA Proteins 0.000 description 1
108091026909 U12 minor spliceosomal RNA Proteins 0.000 description 1
108091026837 U5 spliceosomal RNA Proteins 0.000 description 1
RZZBUMCFKOLHEH-KVQBGUIXSA-N [(2r,3s,5r)-5-(2,6-diaminopurin-9-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 RZZBUMCFKOLHEH-KVQBGUIXSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
238000003453 ammonium sulfate precipitation method Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000001420 bacteriolytic effect Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
238000010805 cDNA synthesis kit Methods 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000011978 dissolution method Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000010362 genome editing Methods 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
229960004359 iodixanol Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
-1 morpholino nucleic acid Chemical class 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
101150022630 prp5 gene Proteins 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000000856 sucrose gradient centrifugation Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
108091035539 telomere Proteins 0.000 description 1
102000055501 telomere Human genes 0.000 description 1
210000003411 telomere Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04002—Adenine deaminase (3.5.4.2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04004—Adenosine deaminase (3.5.4.4)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Mycology (AREA)
Crystallography & Structural Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
User Interface Of Digital Computer (AREA)

IL293671A 2019-12-09 2020-12-08 רנ" א מדריך אנטיסנס עם איזור פונקציונאלי נוסף לעריכת רנ" א מטרה IL293671A (he)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2019222437		2019-12-09
PCT/JP2020/045707 WO2021117729A1 (ja)	2019-12-09	2020-12-08	標的ｒｎａを編集するための機能性領域を付加したアンチセンス型ガイドｒｎａ

Publications (1)

Publication Number	Publication Date
IL293671A true IL293671A (he)	2022-08-01

Family

ID=76329853

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL293671A IL293671A (he)	2019-12-09	2020-12-08	רנ" א מדריך אנטיסנס עם איזור פונקציונאלי נוסף לעריכת רנ" א מטרה

Country Status (13)

Country	Link
US (1)	US20230059753A1 (he)
EP (1)	EP4074825A1 (he)
JP (1)	JPWO2021117729A1 (he)
KR (1)	KR20220111322A (he)
CN (1)	CN114787357A (he)
AU (1)	AU2020399673A1 (he)
BR (1)	BR112022011277A2 (he)
CA (1)	CA3161264A1 (he)
CO (1)	CO2022009538A2 (he)
IL (1)	IL293671A (he)
MX (1)	MX2022006991A (he)
TW (1)	TW202136508A (he)
WO (1)	WO2021117729A1 (he)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109477103A (zh)	2016-06-22	2019-03-15	ProQR治疗上市公司Ⅱ	单链rna-编辑寡核苷酸
AU2020395113A1 (en)	2019-12-02	2022-06-09	Shape Therapeutics Inc.	Therapeutic editing
CN115777020A (zh) *	2020-04-22	2023-03-10	塑造治疗公司	使用snrna组分的组合物和方法
US20240150754A1 (en)	2020-12-25	2024-05-09	Astellas Pharma Inc.	Guide rna for editing polyadenylation signal sequence of target rna
AU2022375788A1 (en) *	2021-10-27	2024-05-23	Shape Therapeutics Inc.	Engineered rnas
WO2023077128A1 (en) *	2021-10-29	2023-05-04	Board Of Regents, The University Of Texas System	Shielded small nucleotides for intracellular barcoding
WO2023152371A1 (en)	2022-02-14	2023-08-17	Proqr Therapeutics Ii B.V.	Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
US20230279397A1 (en)	2022-03-04	2023-09-07	Locanabio, Inc.	Compositions and methods comprising engineered short nuclear rna (snrna)
WO2023196853A1 (en) *	2022-04-05	2023-10-12	Astellas Gene Therapies, Inc.	Compositions and methods for the treatment of muscular dystrophies
WO2023214512A1 (ja) *	2022-05-06	2023-11-09	学校法人常翔学園	人工ｒｎａ分子
WO2024013360A1 (en)	2022-07-15	2024-01-18	Proqr Therapeutics Ii B.V.	Chemically modified oligonucleotides for adar-mediated rna editing
WO2024013361A1 (en)	2022-07-15	2024-01-18	Proqr Therapeutics Ii B.V.	Oligonucleotides for adar-mediated rna editing and use thereof
WO2024044282A1 (en) *	2022-08-24	2024-02-29	Shape Therapeutics Inc.	Engineered constructs for increased transcription of rna payloads
WO2024078345A1 (zh) *	2022-10-11	2024-04-18	广州瑞风生物科技有限公司	snRNA核酸分子及其应用
GB202215614D0 (en)	2022-10-21	2022-12-07	Proqr Therapeutics Ii Bv	Heteroduplex rna editing oligonucleotide complexes
WO2024110565A1 (en)	2022-11-24	2024-05-30	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202218090D0 (en)	2022-12-01	2023-01-18	Proqr Therapeutics Ii Bv	Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en)	2022-12-09	2024-06-13	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en)	2023-01-20	2023-03-08	Proqr Therapeutics Ii Bv	Delivery of oligonucleotides

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5814500A (en) *	1996-10-31	1998-09-29	The Johns Hopkins University School Of Medicine	Delivery construct for antisense nucleic acids and methods of use
JP4936343B6 (ja) *	2008-10-23	2018-06-27	国立大学法人東京大学	ｍｉｃｒｏＲＮＡの機能阻害法
GB201412802D0 (en) *	2014-07-18	2014-09-03	Univ London Queen Mary	Method
DK3234134T3 (da)	2014-12-17	2020-07-27	Proqr Therapeutics Ii Bv	Målrettet rna-redigering
US10550393B2 (en)	2015-03-06	2020-02-04	Tagcyx Biotechnologies	Method for stabilizing DNA aptamers
JP6624743B2 (ja)	2015-07-14	2019-12-25	学校法人福岡大学	部位特異的ｒｎａ変異導入方法およびそれに使用する標的編集ガイドｒｎａならびに標的ｒｎａ−標的編集ガイドｒｎａ複合体
DE102015012522B3 (de)	2015-09-26	2016-06-02	Eberhard Karls Universität Tübingen	Verfahren und Substanzen zur gerichteten RNA-Editierung
SG11201809002RA (en)	2016-04-29	2018-11-29	Univ Nanyang Tech	G-quadruplex-containing antisense oligonucleotides
CN109477103A (zh)	2016-06-22	2019-03-15	ProQR治疗上市公司Ⅱ	单链rna-编辑寡核苷酸
WO2018041973A1 (en)	2016-09-01	2018-03-08	Proqr Therapeutics Ii B.V.	Chemically modified single-stranded rna-editing oligonucleotides
EP3571300A1 (en)	2017-01-19	2019-11-27	ProQR Therapeutics II B.V.	Oligonucleotide complexes for use in rna editing
WO2019071274A1 (en) *	2017-10-06	2019-04-11	Oregon Health & Science University	COMPOSITIONS AND METHODS FOR EDITING RNA
WO2019111957A1 (ja)	2017-12-06	2019-06-13	学校法人福岡大学	オリゴヌクレオチド、その製造方法及び標的ｒｎａの部位特異的編集方法
JP7333508B2 (ja) *	2017-12-06	2023-08-25	学校法人福岡大学	オリゴヌクレオチド、その製造方法及び標的ｒｎａの部位特異的編集方法

2020
- 2020-12-08 BR BR112022011277A patent/BR112022011277A2/pt unknown
- 2020-12-08 EP EP20899155.4A patent/EP4074825A1/en active Pending
- 2020-12-08 CN CN202080084942.6A patent/CN114787357A/zh active Pending
- 2020-12-08 JP JP2021563975A patent/JPWO2021117729A1/ja active Pending
- 2020-12-08 TW TW109143300A patent/TW202136508A/zh unknown
- 2020-12-08 KR KR1020227023235A patent/KR20220111322A/ko unknown
- 2020-12-08 IL IL293671A patent/IL293671A/he unknown
- 2020-12-08 WO PCT/JP2020/045707 patent/WO2021117729A1/ja unknown
- 2020-12-08 AU AU2020399673A patent/AU2020399673A1/en active Pending
- 2020-12-08 US US17/783,591 patent/US20230059753A1/en active Pending
- 2020-12-08 CA CA3161264A patent/CA3161264A1/en active Pending
- 2020-12-08 MX MX2022006991A patent/MX2022006991A/es unknown
2022
- 2022-07-07 CO CONC2022/0009538A patent/CO2022009538A2/es unknown

Also Published As

Publication number	Publication date
WO2021117729A1 (ja)	2021-06-17
CA3161264A1 (en)	2021-06-17
CO2022009538A2 (es)	2022-07-19
JPWO2021117729A1 (he)	2021-06-17
BR112022011277A2 (pt)	2022-09-06
EP4074825A1 (en)	2022-10-19
MX2022006991A (es)	2022-08-25
CN114787357A (zh)	2022-07-22
KR20220111322A (ko)	2022-08-09
TW202136508A (zh)	2021-10-01
US20230059753A1 (en)	2023-02-23
AU2020399673A1 (en)	2022-07-28

Publication	Publication Date	Title
IL293671A (he)	2022-08-01	רנ" א מדריך אנטיסנס עם איזור פונקציונאלי נוסף לעריכת רנ" א מטרה
US20220275359A1 (en)	2022-09-01	Guide rna for editing target, with functional nucleotide sequence added
US20190307785A1 (en)	2019-10-10	Compositions comprising circular polyribonucleotides and uses thereof
JP4321877B2 (ja)	2009-08-26	トランス―スプライスにより生成される治療用分子
EP2996697B1 (en)	2019-06-26	Intracellular translation of circular rna
Nakaar et al.	1994	Upstream tRNA genes are essential for expression of small nuclear and cytoplasmic RNA genes in trypanosomes
CN113661242A (zh)	2021-11-16	包含经修饰的环状多核糖核苷酸的组合物及其用途
WO2010084371A1 (en)	2010-07-29	Novel circular interfering rna molecules
US11939580B2 (en)	2024-03-26	Construct of self-circularization RNA
TW201210611A (en)	2012-03-16	Treatment of Nicotinamide Phosphoribosyltransferase (NAMPT) related diseases by inhibition of natural antisense transcript to NAMPT
EP1639112B1 (en)	2015-04-01	Novel beta-actin and rps21 promoters and uses thereof
JP2023002469A (ja)	2023-01-10	抗ウイルス及び抗がんワクチンに用いる新規なｍＲＮＡ組成物及びその製造方法
US20200392496A1 (en)	2020-12-17	Oligonucleotides, manufacturing method for same, and target rna site-specific editing method
TW201735932A (zh)	2017-10-16	使用微核醣核酸前驅物作爲誘導ｃｄ３４陽性成體幹細胞增殖之藥物
EP4269585A1 (en)	2023-11-01	Guide rna for editing polyadenylation signal sequence of target rna
CN116162609A9 (zh)	2024-05-14	Cas13蛋白、CRISPR-Cas***及其应用
KR20190015845A (ko)	2019-02-15	목적 유전자 발현 조절을 위한 대장균 및 코리네박테리움 글루타미쿰 셔틀 벡터
EP3964582A1 (en)	2022-03-09	Oligomeric nucleic acid molecule, and application thereof in acute intermittent porphyria treatment
WO2021137742A1 (ru)	2021-07-08	Генотерапевтический днк-вектор
JP2022189717A (ja)	2022-12-22	ｉＰＳ細胞の生成に使用される新規ＲＮＡ組成物およびその製造方法
KR20220067468A (ko)	2022-05-24	세포질에서 자가 전사가 가능하고 발현억제 rna를 제공하는 rna/dna 시스템
CN117821506A (zh)	2024-04-05	一种转基因质粒及其构建方法